Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications

Baylor College of Medicine and the Methodist Hospital, Houston, Texas, USA.

OBJECTIVES: We sought to evaluate the impact of angiographically visible thrombus on short- and long-term clinical outcomes after percutaneous transluminal coronary angioplasty (PTCA). BACKGROUND: Intracoronary thrombus is frequently seen on angiography in patients with acute ischemic coronary syndromes or complex lesion morphology, or both, and is often considered to predict a higher rate of complications in patients undergoing PTCA. METHODS: Prospectively collected data from 2,099 patients undergoing high risk PTCA in the Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications (EPIC) trial were analyzed. In addition to aspirin and heparin, patients were randomized to receive either abciximab bolus and infusion, abciximab bolus alone or placebo. Based on an angiographic core laboratory interpretation, patients were classified into three groups: thrombus absent, thrombus possible or thrombus present. The primary end point at 30 days was the composite of death, myocardial infarction or urgent revascularization. The 6-month end point was the composite of death, myocardial infarction or any revascularization. RESULTS: Although abrupt closure was most common in patients with thrombus present compared with thrombus absent or possible (13%, 10.0% and 7.4%, respectively), neither the 30-day nor the 6-month clinical end points were different among the three groups (9%, 11% and 11.7%, respectively, and 30%, 34% and 31%, respectively). Most notably, the benefit of treatment with abciximab was present in all three thrombus groups, and the magnitude of benefit was not different among the thrombus groups. CONCLUSIONS: In high risk patients undergoing percutaneous coronary revascularization, features of thrombus on the preprocedure angiogram do not indicate an augmented risk of adverse clinical outcomes. Abciximab therapy reduces the rate of adverse outcomes regardless of the presence of thrombus and should therefore not necessarily be reserved for patients whose angiograms have features of intraluminal thrombus.

This article has been cited by other articles:

				R. S. Wright, J. L. Anderson, C. D. Adams, C. R. Bridges, D. E. Casey Jr, S. M. Ettinger, F. M. Fesmire, T. G. Ganiats, H. Jneid, A. M. Lincoff, et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J. Am. Coll. Cardiol., May 10, 2011; 57(19): e215 - e367. [Full Text] [PDF]

				J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation, May 10, 2011; 123(18): e426 - e579. [Full Text] [PDF]

				M. Srinivasan, C. S. Rihal, M. Singh, R. J. Lennon, D. R. Holmes, and A. Prasad Percutaneous Coronary Intervention in Native Vessels With Angiographically Visible Thrombus: Temporal Trends and Impact of Drug-Eluting Stents J. Am. Coll. Cardiol. Intv., September 1, 2010; 3(9): 937 - 946. [Abstract] [Full Text] [PDF]

				J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF]

				I. Mizote, Y. Ueda, T. Ohtani, M. Shimizu, Y. Takeda, T. Oka, M. Tsujimoto, A. Hirayama, M. Hori, and K. Kodama Distal Protection Improved Reperfusion and Reduced Left Ventricular Dysfunction in Patients With Acute Myocardial Infarction Who Had Angioscopically Defined Ruptured Plaque Circulation, August 16, 2005; 112(7): 1001 - 1007. [Abstract] [Full Text] [PDF]

				M. Marzilli, G. Sambuceti, R. Testa, and S. Fedele Platelet glycoprotein IIb/IIIa receptor blockade and coronary resistance in unstable angina J. Am. Coll. Cardiol., December 18, 2002; 40(12): 2102 - 2109. [Abstract] [Full Text] [PDF]

				M. Singh, G. S. Reeder, E. M. Ohman, V. Mathew, W. B. Hillegass, R. D. Anderson, D. S. Gallup, K. N. Garratt, and D. R. Holmes Jr Does the presence of thrombus seen on a coronary angiogram affect the outcome after percutaneous coronary angioplasty? An angiographic trials pool data experience J. Am. Coll. Cardiol., September 1, 2001; 38(3): 624 - 630. [Abstract] [Full Text] [PDF]

				E. Braunwald, E. M. Antman, J. W. Beasley, R. M. Califf, M. D. Cheitlin, J. S. Hochman, R. H. Jones, D. Kereiakes, J. Kupersmith, T. N. Levin, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) J. Am. Coll. Cardiol., September 1, 2000; 36(3): 970 - 1062. [Full Text] [PDF]

				C. Heeschen, M. J. van den Brand, C. W. Hamm, and M. L. Simoons Angiographic Findings in Patients With Refractory Unstable Angina According to Troponin T Status Circulation, October 5, 1999; 100(14): 1509 - 1514. [Abstract] [Full Text] [PDF]

				V. Mathew, D. E. Grill, C. G. Scott, J. A. Grantham, H. H. Ting, K. N. Garratt, and D. R. Holmes Jr. The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1163 - 1169. [Abstract] [Full Text] [PDF]

				S. G. Ellis, A. M. Lincoff, D. Miller, J. E. Tcheng, N. S. Kleiman, D. Kereiakes, R. Califf, E. J. Topol, and for the EPIC and EPILOG Investigators Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology J. Am. Coll. Cardiol., November 15, 1998; 32(6): 1619 - 1623. [Abstract] [Full Text] [PDF]